{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T10:27:56Z","timestamp":1793528876199,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euo.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:04:39Z","timestamp":1773817479000},"page":"1033-1038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathways"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-5777","authenticated-orcid":false,"given":"Anwar R.","family":"Padhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Carlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Bratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.03.002_b0005","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.eururo.2017.02.026","article-title":"What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology prostate cancer guidelines panel","volume":"72","author":"Moldovan","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.002_b0010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2025.05.038","article-title":"Magnetic resonance imaging-based biopsy strategies in prostate cancer screening: a systematic review","volume":"88","author":"Schoots","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.002_b0015","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.eururo.2018.12.014","article-title":"Guidelines for reporting of statistics for clinical research in urology","volume":"75","author":"Assel","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.002_b0020","article-title":"Update on PI-RADS version 2.1 diagnostic performance benchmarks for prostate MRI: systematic review and meta-analysis","volume":"312","author":"Oerther","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.euo.2026.03.002_b0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bju.15277","article-title":"Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation","volume":"127","author":"Schoots","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.03.002_b0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/bjr\/tqad027","article-title":"Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making","volume":"97","author":"Rajendran","year":"2024","journal-title":"Br J Radiol"},{"key":"10.1016\/j.euo.2026.03.002_b0035","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.eururo.2024.08.022","article-title":"VISION: an individual patient data meta-analysis of randomised trials comparing magnetic resonance imaging targeted biopsy with standard transrectal ultrasound guided biopsy in the detection of prostate cancer","volume":"87","author":"Kasivisvanathan","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.002_b0040","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.03.002_b0045","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.euo.2026.03.002_b0050","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","article-title":"Results after four years of screening for prostate cancer with PSA and MRI","volume":"391","author":"Hugosson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.03.002_b0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54577","article-title":"Repeated prostate cancer screening using prostate-specific antigen testing and magnetic resonance imaging: a secondary analysis of the STHLM3-MRI randomized clinical trial","volume":"7","author":"Nordstr\u00f6m","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2026.03.002_b0060","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.euo.2023.09.013","article-title":"Magnetic resonance imaging-targeted versus systematic prostate biopsies: 2-year follow-up of a prospective randomized trial (PRECISE)","volume":"7","author":"Klotz","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.002_b0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jamaoncol.2024.5497","article-title":"Oncological safety of MRI-informed biopsy decision-making in men with suspected prostate cancer","volume":"11","author":"Hamm","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2026.03.002_b0070","unstructured":"Ng CPY, Light A, Eragamreddy SK, et al. Five-year outcomes for men after negative magnetic resonance imaging (MRI) or negative biopsy in the RAPID MRI-directed prostate cancer diagnostic pathway. Eur Urol, in press."},{"key":"10.1016\/j.euo.2026.03.002_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103022","article-title":"Monitoring of prostate cancer screening in the European Union: development of key performance indicators through the PRAISE-U project","volume":"80","author":"Singh","year":"2025","journal-title":"EClinicalMedicine"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:33:21Z","timestamp":1793525601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2588931126000611"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.03.002","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathways","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}